2-methyl-5-(pyrrolidin-3-yl)pyridine | 1225218-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-methyl-5-(pyrrolidin-3-yl)pyridine
• 英文别名: 2-methyl-5-pyrrolidin-3-ylpyridine
• CAS: 1225218-29-0
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: RNWIAHGPFLARLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1<br/>[FR] INHIBITEURS DE LA 11BÊTA-HYDROXYSTÉROÏDE-DÉSHYDROGÉNASE 1 À BASE DE CARBAMATES ET D'URÉE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2010141424A1

  公开（公告）日：2010-12-09

  This invention relates to novel compounds of the invention pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  这项发明涉及本发明的新化合物及其药用盐，以及其药物组合物，这些化合物对于治疗与哺乳动物中的11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
• [EN] MONOCYCLIC OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA MONOCYCLIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018109202A1

  公开（公告）日：2018-06-21

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，用于制备这类化合物和组合物的方法，以及这类化合物和组合物在抑制OGA有益的疾病的预防和治疗中的用途，例如tau病变，特别是阿尔茨海默病或进行性上核性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化症或前颞叶痴呆症。
• CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Claremon David A.

  公开号：US20110053943A1

  公开（公告）日：2011-03-03

  This invention relates to novel compounds of the invention pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及本发明的新化合物及其药学上可接受的盐和药物组合物，对于治疗与哺乳动物中的11β-HSD1的调节或抑制相关的疾病是有用的。本发明还涉及所述新化合物的药物组合物和其在细胞中降低或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• [EN] HPK1 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE HPK1 ET LEURS UTILISATIONS
  申请人：NIMBUS SATURN INC

  公开号：WO2022174253A1

  公开（公告）日：2022-08-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们抑制HPK1和治疗HPK1介导的疾病的方法。
• PYRROLOTRIAZINE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2051980B1

  公开（公告）日：2014-02-26